- Taschenbuch: 304 Seiten
- Verlag: Smithsonian Inst Pr; Auflage: First. (Januar 2004)
- Sprache: Englisch
- ISBN-10: 0805075089
- ISBN-13: 978-0805075083
- Größe und/oder Gewicht: 21,7 x 14 x 2,1 cm
- Amazon Bestseller-Rang: Nr. 1.494.881 in Englische Bücher (Siehe Top 100 in Englische Bücher)
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| |||||||||||||||
Produktinformation |
Mehr über den Autor
Entdecken Sie Bücher, lesen Sie über Autoren und mehr
› Besuchen Sie die Seite von Tom Abate auf Amazon
› Besuchen Sie die Seite von Tom Abate auf Amazon
Produktbeschreibungen
From Booklist
For investors having a hard time grasping concepts in computer technology, the biotechnology business is even more mystifying. With futuristic names like Genentech, Protein Design Labs, and Human Genome Sciences, an excruciatingly long product development cycle, and very light coverage by analysts, this sector is one of the most difficult for the stock-buying public to understand. However, despite a few public mishaps of their own, biotech stocks as a whole have held up better through the downturn than the overall tech sector. Abate is one of the few writers who closely watch this area, and writes the "BioScope" column for the San Francisco Chronicle. He admits that biotech stocks are among some of the most difficult to play, and warns against jumping into any of the speculative startups in this field. Instead he recommends most investors stick to the handful of companies that have already shown a profit. With plenty of charts and detailed coverage of many individual companies, this would be an excellent source to begin research on this area of cutting-edge medicine. David Siegfried
Copyright © American Library Association. All rights reserved -- Dieser Text bezieht sich auf eine vergriffene oder nicht verfügbare Ausgabe dieses Titels.
Copyright © American Library Association. All rights reserved -- Dieser Text bezieht sich auf eine vergriffene oder nicht verfügbare Ausgabe dieses Titels.
Pressestimmen
“An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come.” —Brook H. Byers, partner, Kleiner Perkins Caufield & Byers
In diesem Buch
(Mehr dazu)
Einleitungssatz
In 1953, two young scientists made an obscure discovery that would profoundly affect the way we diagnose disease, discover medicines, raise crops and animals, and make every chemical from detergents to clean-burning fuels. Lesen Sie die erste Seite
Buchdeckel | Copyright | Inhaltsverzeichnis | Auszug | Stichwortverzeichnis | Rückseite
In 1953, two young scientists made an obscure discovery that would profoundly affect the way we diagnose disease, discover medicines, raise crops and animals, and make every chemical from detergents to clean-burning fuels. Lesen Sie die erste Seite
Mehr entdecken
Wortanzeiger
Ausgewählte Seiten ansehenWortanzeiger
Buchdeckel | Copyright | Inhaltsverzeichnis | Auszug | Stichwortverzeichnis | Rückseite
Tags(Was ist das?)Bei einem Tag handelt es sich um ein Schlagwort, das zum Produkt passt.
Tags erleichtern allen Kunden die Suche und die Sortierung ihrer Lieblingsprodukte. |
Eine digitale Version dieses Buchs im Kindle-Shop verkaufen
Wenn Sie ein Verleger oder Autor sind und die digitalen Rechte an einem Buch haben, können Sie die digitale Version des Buchs in unserem Kindle-Shop verkaufen.
Weitere Informationen
Kundenrezensionen
Es gibt noch keine Kundenrezensionen auf Amazon.de
5 Sterne
4 Sterne
3 Sterne
2 Sterne
1 Sterne
Die hilfreichsten Kundenrezensionen auf Amazon.com (beta)
Amazon.com:
5 Rezensionen
14 von 14 Kunden fanden die folgende Rezension hilfreich
A strong dose of reality to the often hype driven sector
24. April 2003
Format:Gebundene Ausgabe
Tom Abate has been covered the Biotech industry for the San Francisco Chronicle for years. It shows. He brings a strong dose of reality to this hype driven sector.
Who this book is for:
-Independent investors willing to spend a lot of time doing research
-People looking for a current industry overview
-Job seekers
The Good:
-Extremely well written
-Up to Date (as of spring 2003)
-Knowledgeable - several small tidbits of data pay for the book by themselves
The Bad:
-Will quickly go out of date. For example the Appendix contains a list of firm websites and market caps; Market Caps change - companies disappear.
-Not enough FDA information. This should have been a separate chapter covering the FDA approval process in detail as well as other countries' processes.
-Too much basic investment advice: firm valuation/free cash flow/ portfolio theory / investor risk profile. Other books do a better, more thorough job of this.
-No bibliography
I gave it 5 stars because if you are going to invest in biotech the book will more than pay for itself.
10 von 11 Kunden fanden die folgende Rezension hilfreich
Well structured and interesting
16. September 2003
Format:Gebundene Ausgabe
An excellent introduction to biotech investing.
Tom Abate is a good writer and knows his subject. I thought this book was written in a guarded, pragmatic way that suits the reader's purpose (presumably investment). The dustjacket shouts of a 'coming boom' but the author can be forgiven for what is basically puffery. Abate is clearly arguing for a period of drawn out growth fuelled by demographics and accelerating technical progress - not an imminent goldrush.
I gained a number of insights I consider valuable:
-An understanding of the mechanism of FDA approval and how companies manage themselves around it.
-The fluid business models of existing companies.
-The way in which institutional fund managers seem to advocate active trading over a 'buy and hold' approach to biotech portfolios (this surprised me).
Timely, relevant and convincingly argued. I'd probably buy another book by this author.
3 von 3 Kunden fanden die folgende Rezension hilfreich
If you are an investor looking at biotech, you should read this book
14. August 2009
Format:Taschenbuch
As our population ages, there are more opportunities for companies involved in treating diseases. Companies in the biotech industry have a bright future. But, the author says that investing in biotech is risky. This is understandable because the firms in this industry rely heavily on innovation. New discoveries can make current products obsolete. Many investors lost money investing in these companies because they do not understand the industry and individual companies.
I liked how the author distinguished between high-tech and biotech companies. Successful high-tech companies develop valuable networks. For example, Microsoft has a network of software developers who tailor their programs to run on Windows. Biotech, on the other hand, is an industry of niches. The industry is complicated compared with other industries. However, the author did a good job making it more understandable to readers.
- Mariusz Skonieczny, author of Why Are We So Clueless about the Stock Market? Learn how to invest your money, how to pick stocks, and how to make money in the stock market
I liked how the author distinguished between high-tech and biotech companies. Successful high-tech companies develop valuable networks. For example, Microsoft has a network of software developers who tailor their programs to run on Windows. Biotech, on the other hand, is an industry of niches. The industry is complicated compared with other industries. However, the author did a good job making it more understandable to readers.
- Mariusz Skonieczny, author of Why Are We So Clueless about the Stock Market? Learn how to invest your money, how to pick stocks, and how to make money in the stock market
Waren diese Rezensionen hilfreich?
Wir wollen von Ihnen hören.
Kunden diskutieren
|
Das Forum zu diesem Produkt
Fragen stellen, Meinungen austauschen, Einblicke gewinnen Aktive Diskussionen in ähnlichen Foren
Kundendiskussionen durchsuchen
|
Ähnliche Foren
|
||||||||||||||||||||||||||||||||||
Lieblingslisten
Ähnliche Artikel finden
- Fremdsprachige Bücher > Business, Karriere & Geld > Industriezweige & Berufe
- Fremdsprachige Bücher > Business, Karriere & Geld > Investieren > Aktien
- Fremdsprachige Bücher > Business, Karriere & Geld > Investieren > Einführungen
- Fremdsprachige Bücher > Business, Karriere & Geld > Persönliche Finanzen
Anhand des Sachgebietes nach ähnlichen Produkten suchen:
Ihr Kommentar
Möchten Sie die Produktinformationen aktualisieren oder Feedback zu den Produktabbildungen geben?
|
